Articles tagged with Kidney Cancer
A phase II trial of axitinib has shown promising activity in patients with cytokine-refractory, metastatic kidney cancer. In the trial, 23 patients had complete or partial responses, with some responses lasting up to 26 months.
A study presented at the European Cancer Conference found that axitinib shrank tumours and delayed disease progression in patients with advanced kidney cancer. The drug, which is also being tested in other types of cancer, showed promising results in a group of heavily pre-treated patients.
Reactivating a key gene, sFRP-1, has been shown to stop tumor growth and reduce metastasis in clear cell renal cell carcinoma. The study found that sFRP-1 controlled 13 tumor-promoting genes along the Wnt signaling pathway, which is linked to various cancers.
A combination of two drugs, interferon alpha and sorafenib, is more effective than either drug alone in treating renal cell carcinoma, the most common form of kidney cancer. The treatment doubles the survival time of patients with stage IV disease.
A new imaging technique using Indocyanine Green (ICG) dye helps surgeons precisely remove cancerous tumors from the kidney while sparing as much healthy tissue as possible. This innovation allows for more effective treatment and better patient outcomes.
The Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial demonstrated Nexavar's effectiveness in extending overall survival by 44% compared to placebo. Hepatocellular carcinoma is the most common form of liver cancer, responsible for about 90% of primary malignant liver tumors in adults.
Pazopanib, an oral angiogenesis inhibitor, demonstrated a 27% week 12 response rate and 73% total disease control rate in patients with advanced renal cell carcinoma. The study showed clear clinical activity in treating this type of cancer.
Pazopanib demonstrated high response rates of 27% and stable disease in 46% of patients with advanced renal cell carcinoma (RCC). In ovarian cancer, pazopanib showed biological activity in 41% of evaluable patients. These findings support further investigations into pazopanib's therapeutic potential.
A phase III clinical study shows temsirolimus improves overall survival in patients with advanced renal cell carcinoma compared to standard treatment interferon. The treatment was also better tolerated, with fewer severe side effects.
Researchers at Johns Hopkins found that cancer cells can reprogram themselves to use less oxygen and more glucose, allowing them to survive and spread. The loss of a single gene causes cancer cells to stop making mitochondria, leading to the use of fermentation for energy production.
The European Association of Urology (EAU) has recommended Sutent as a first-line treatment for patients with metastatic renal cell carcinoma. Clinical trials have shown that Sutent improves progression-free survival by more than doubling the median PFS compared to interferon-alpha. The new guidelines also highlight Sutent's higher obje...
A pivotal Phase III trial demonstrated Nexavar's efficacy and clinical benefit in patients with advanced renal cell carcinoma. The study showed a median progression-free survival of 5.5 months for patients receiving Nexavar, compared to 2.8 months for those on placebo.
A study found that kidney transplantation increases the risk of certain cancers, including nonmelanoma skin cancer and Kaposi sarcoma. The overall incidence of cancer was 3.27 times higher after transplantation compared to before or during dialysis.
Researchers found that pre-surgical treatment with bevacizumab and erlotinib is safe and effective in prolonging patients' survival. The study suggests this approach might be applicable to a wide range of patients with renal cell carcinoma.
A large Italian case-control study found a significant association between high bread consumption and an increased risk of renal cell carcinoma. The study also discovered that consuming more vegetables may lower the risk, while eating pasta and rice may raise it.
A large study published in Environmental Health journal reveals that IBM factory workers in the US are more likely to die from cancer than the general population. The study confirms previous findings and highlights clear health risks for computer factory workers worldwide.
A major study from Karolinska Institutet found that eating fatty fish like salmon, sardines, and mackerel at least once a week reduces kidney cancer risk by up to 74% over a decade. The study also highlights the protective effects of omega-3 fatty acids and vitamin D in fatty fish.
A large cohort study found that women who consumed one or more servings of fatty fish per week had a 44% decreased risk of renal cell carcinoma compared to those who did not consume any fish. Fatty fish consumption was also associated with higher levels of omega-3 fatty acids and vitamin D, which may contribute to the reduced risk.
A University of Michigan Health System study found that while more small kidney tumors are being detected and treated, the death rate from kidney cancer is not decreasing. The researchers suggest re-examining treatment strategies for patients with small renal masses, as surgery may not be the best option for everyone.
The incidence of kidney cancer has risen over the past two decades, with small renal masses accounting for most cases. Despite increased surgeries, mortality rates have not decreased, suggesting that current treatments may not be effective for these slow-growing tumors.
A global study has shown a clear association between kidney cancer incidence rates and proximity to the equator, suggesting that UVB exposure triggers vitamin D production. Countries near the equator have lower kidney cancer rates, while those farther away have higher rates, indicating a potential protective effect of sunlight exposure.
A retrospective study by Memorial Sloan-Kettering Cancer Center suggests that radical nephrectomy is a significant risk factor for developing chronic kidney disease. Patients who underwent partial nephrectomy had a lower rate of chronic kidney disease and better kidney function after surgery.
Researchers at Thomas Jefferson University have identified proepithelin as a crucial protein in the spread of bladder cancer. The study found that proepithelin promotes migration and invasion of bladder cancer cells, suggesting it could be a potential target for new drugs.
The study found that B7-H4, an immune system blocker, is present in aggressive kidney cancers and vessels, allowing the cancer to grow and spread. This discovery may lead to better treatment options for patients with renal cell carcinoma, a deadly form of kidney cancer.
A recent study published by Memorial Sloan Kettering Cancer Center has shown that a targeted therapy called sunitinib is effective in treating patients with advanced kidney cancer. The study found that sunitinib significantly improved progression-free survival and tumor shrinkage compared to standard treatment with interferon-alpha.
A majority of patients with small kidney tumors have their entire kidney removed, despite the availability of organ-sparing surgery. Studies show that partial nephrectomy is just as effective in controlling cancer while preserving long-term kidney function. However, its infrequent use may be due to surgeon expertise and hospital policies.
Researchers found that human kidney cancer cells lacking the tumor suppressor gene Von Hippel Lindau were more sensitive to CCI-779 due to high levels of hypoxia-inducible factor (HIF). The study identified a test to predict which patients will benefit from receiving CCI-779, potentially helping 20,000 kidney cancer patients annually.
A recent study by Mayo Clinic researchers found that only about 4.5% of aggressive kidney tumors express KIT, a receptor kinase tyrosine, and no mutations were detected in most cases. This suggests that imatinib therapy may not be effective for these patients, despite previous studies suggesting its potential benefits.
A new Stanford tool helps identify subtypes of kidney tumors based on gene activity, potentially leading to more targeted and effective treatments. The approach minimizes setbacks in clinical relevance by identifying relevant genes across multiple studies.
A new vaccine-based approach has been shown to prolong disease progression in patients with renal cancer and malignant melanoma. The therapy, which uses latex or silica beads, was found to stabilise and control disease for an average of one year. In contrast, standard treatments have limited efficacy and are often toxic.
Despite declining overall mortality, US cancer incidence rose slightly among women in 2002 compared to the previous decade. The study also found that some cancers, like leukemia and non-Hodgkin lymphoma, experienced increased incidence.
Renal transplant recipients are at increased risk for melanoma due to immunosuppression, with a 3.6-fold increase in incidence compared to the general population. The risk increases five percent per year after transplantation and is greater in men, who also experience rapid age-related increases.
A new kidney cancer drug has shown a partial response rate of 40% in patients with metastatic renal cell carcinoma, significantly higher than the standard treatment's 15% response rate. The medication, SU11248, was well-tolerated and had significant side effects, but offered improved survival rates for some patients.
Researchers at Fox Chase Cancer Center have developed a non-invasive test to monitor kidney cancer patients by analyzing DNA methylation patterns in urine samples. The test, called methylation-specific polymerase chain reaction (PCR), can detect even a few cancer cells among healthy cells with high specificity.
Researchers at the Mayo Clinic have identified a potential biomarker for aggressive kidney cancer, which can help improve treatment outcomes by identifying patients at high risk of disease progression. The study found that high levels of B7-H1 molecule are associated with increased risk of cancer spread and mortality.
A new treatment using radiofrequency ablation has been shown to be effective in eliminating kidney tumors, with complete ablation achieved in 83% of patients. The treatment is particularly promising for patients who are not ideal candidates for surgery due to other health-related conditions.
BAY 43-9006 demonstrates durable disease stabilization or tumor shrinkage in 89 participants with renal cell carcinoma. The study also shows an estimated median time to tumor progression of 48 weeks, with 88% of patients remaining progression-free at six months.
A new investigational drug has shown promise in treating kidney cancer, producing durable responses and stable disease in patients. The study found that nearly two-thirds of patients experienced stable disease after 12 weeks, and the median time to progression was nearly one year.
Researchers have found a novel agent, SU11248, to be highly effective in treating advanced renal cell carcinoma. The treatment has shown significant activity in patients whose cancer had failed to respond to standard therapy.
Researchers at the University of Pittsburgh have identified a potential biomarker, RCCA-5, which may help detect renal cell carcinoma in its early stages. Early detection is crucial for effective treatment, and RCCA-5 shows promise as an effective marker for urologic cancers.
Researchers developed a non-invasive test to detect kidney cancer using gene changes found in urine samples. The test accurately identified stage I disease and showed no false positives.
Researchers at UCLA successfully deliver gene therapy agents directly into tumor cells with minimal complications, improving effectiveness and reducing side effects of existing treatments. The study demonstrates the feasibility and safety of CT-guided injection for gene therapy delivery.
A new vaccine has shown significant improvement in 5-year progression-free survival rates for patients with renal cancer, with a 77% rate in the vaccinated group compared to 68% in the control group. The well-tolerated treatment was associated with only 12 adverse events.
A new urine-based test has been developed to detect kidney cancer, showing promising results in early diagnosis. The test identified gene changes in the urine of patients with kidney cancer that matched those found in tumor samples, indicating its potential as a diagnostic tool.
A new CT scan technique called multi-detector CT urography (MDCTU) has been shown to detect various urinary system problems, including bladder cancer, kidney stones, and cysts. The technique is more accurate than traditional methods and may be beneficial for high-risk patients.
BAY 43-9006 shows promise as a treatment for kidney cancer, with 42% of patients experiencing tumor shrinkage. The compound targets both Raf kinase and VEGFR2, inhibiting tumor growth and angiogenesis.
A phase II trial found that 42% of patients with metastatic kidney cancer experienced at least a 25% reduction in tumor size, with 6 patients experiencing a 50% or greater response. The study's innovative design validated a new approach to phase II trial design.
Researchers found that patients with smoking-related cancers had shorter telomeres than those without cancer, and that short telomeres were associated with a greater cancer risk. Smoking status significantly influenced the effect of short telomeres on cancer risk.
Researchers report successful treatment of 50 out of 51 renal tumors using radiofrequency ablation. The therapy is particularly effective for tumors on the outer surface of the kidney due to surrounding fat insulation.
Research suggests that diet is a second leading cause of cancer, accounting for approximately 30% of cancers in developed countries. A healthy weight, restricted alcohol consumption, and a balanced diet rich in fruits, vegetables, and cereals can help reduce cancer risk.
USC researchers propose lipid peroxidation as a mechanism for renal cell carcinoma, uniting known risk factors such as obesity and high blood pressure. The process creates DNA damage that can lead to cancer mutations, increasing kidney cancer risk.
Researchers at Rotterdam University Hospital develop genetically engineered T cells to target kidney cancer. The therapy combines the cellular immune system with the humoral immune system, offering a promising treatment option for patients with metastases.
A patient who developed kidney failure after taking Chinese herbal medicine containing aristolochic acid has now been diagnosed with kidney cancer. The authors warn of the carcinogenic potential of aristolochic acid in human beings.
A Mayo Clinic study finds that less radical surgery for kidney cancer is equally effective to radical alternative and less likely to cause failure in the second kidney. Long-term survival rates between the two procedures were identical, but patients undergoing less radical surgery had a lower risk of developing renal failure.
A Phase I/II study found substantial and occasional complete regression of widespread tumors in patients with treatment-resistant metastatic renal cell carcinoma treated with blood stem cell transplants. Three patients achieved total regression, while seven showed partial regression of disease.